Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Watch on earnings: Quarterly test volume growth rate and sequential trends (leading indicator of revenue trajectory), Medicare coverage policy updates for comprehensive genomic profiling (CGP) and liquid biopsy tests, Average reimbursement rate per test from commercial payers and Medicare.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $1.0B to $1.2B as quarterly test volume growth rates and trajectory toward profitability milestones.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
